Company Announcements

CPI International named General Manager Jarrett Wendt president and CEO in October.

In October, BioSurplus opened a sales office in Incheon, South Korea, in partnership with jDepot.

In October, Agilent and the Agilent Technologies Foundation selected Steven Carr, PhD, who directs the Proteomics Platform at the Broad Institute of MIT and Harvard, for an Agilent Thought Leader Award. The $1.2 million award will support his work in developing technology to analyze proteins and peptides and includes the donation of a liquid handling system, a chip-based nano-HPLC system and a triple quadrupole LC/MS system.

In October, Agilent announced an expansion of an existing partnership into an exclusive agreement to provide Oxford Gene Technology (OGT) with oligonucleotide microarrays, as part of its OEM supply agreement, and SureSelect target enrichment products for OGT’s next-generation sequencing services.

Roche Diagnostics’ third-quarter sales for its Applied Science division grew 1% at constant exchange rates (CER) to CHF 167 million ($201 million). Year-to-date sales declined 2% in CER to CHF 646 million ($778 million) to make up 8% of division sales. Year to date, Applied Science revenue for North America grew 2% but declined 6% for Europe/Middle East/Africa and was down 4% for Rest of World to make up 38%, 40% and 22% of sales, respectively. Year to date in CER, Custom Biotech sales grew 12%, qPCR and Nucleic Acid Purification sales were down 4%, and Genomic Analysis sales dropped 12%.

In an October filing with the SEC, Polysciences disclosed that it raised $4 million in a debt offering.

GE announced in its third-quarter conference call that GE Healthcare Life Sciences revenue increased 12%.

Hitachi High-Technologies’ fiscal 2012 second-quarter sales for Science and Medical Systems rose 31.0% to ¥40,100 million ($516 million) (see IBO 10/31/11): Analytical Instruments sales fell 13.6% to ¥3,800 million ($49 million), Electron Microscopes sales revenue grew 11.4% to ¥8,800 million ($113 million), Clinical Analyzers sales rose 48.2% to ¥20,600 million ($265 million) and Biotechnology Products/Other revenue grew 52.3% to ¥6,700 million ($86 million). Division sales are expected to grow 15% for the fiscal year, with Electron Microscopes sales up 8%, Clinical Analyzers sales up 6%, Biotechnology Products/Other sales up 1% and Analytical Instruments sales down 10%.

Hitachi High-Technology announced in October its Medium-term Management Plan 2013 and its Long-term Management Strategy.

The Long-term Strategy includes investment focuses on the life science, environment and new energy fields and 67% foreign sales in fiscal 2021. The Medium-term Plan includes accelerated global sales and manufacturing and new business creation activities, including solutions for drug-manufacturing processes.

In October, Biotage appointed Erika Söderberg Johnson CFO and business controller, effective January 1, 2012. She was previously the CFO of Karo Bio.